Genmab launches US$502m IPO
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
Dutch biopharma company AM-Pharma B.V. has secured 116m to bring its acute kidney injury treatment into Phase III.
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform.
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised 28.5m to develop its microalgae portfolio for nutrition and cosmetics.
French biotech Osivax has raised 8m to fast-track development of its lead flu vaccine candidate and branch out to Belgium.
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to 10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.